Mission Therapeutics, a drug discovery and development company focused on targeting the ubiquitin pathway, and AbbVie (NYSE: ABBV) today announced progression of selected deubiquitylating enzyme (DUB) targets into the next phase of research in their neurodegenerative disease collaboration.
MISSION Therapeutics is a specialist pharmaceutical company whose aim is to translate new molecular understandings of human cell biology into drugs that will markedly improve the management of life-threatening diseases, particularly cancer.
Telephone: +44 (0)1223 607 340
The Glenn Berge Building Building 940 Babraham Research Campus, Babraham Cambridge
Post Code: CB22 3FH
Country: United Kingdom
Membership Type: Corporate 21-50